Nimesulide and indomethacin induce apoptosis in head and neck cancer cells

Martina Pelzmann1, Dietmar Thurnher, Claudia Gedlicka

  • 1Department of Otorhinolaryngology, University of Vienna, Währinger Gürtel, Vienna, Austria. martina.pelzmann@aon.at

Abstract

Insights

Non-steroidal anti-inflammatory drugs (NSAIDs) targeting cyclooxygenase-2 (COX-2) show potential in treating head and neck squamous cell carcinoma (HNSCC). These drugs induce cancer cell death and reduce cell numbers, suggesting a role in HNSCC therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) enzymes.
  • Both COX-1 and COX-2 isoforms are implicated in cancer development.
  • Head and Neck Squamous Cell Carcinoma (HNSCC) is a significant area of oncological research.

Purpose of the Study:

  • To investigate the effects of COX-2 selective (nimesulide) and non-selective (indomethacin) NSAIDs on HNSCC cell lines.
  • To assess the impact of these NSAIDs on cancer cell proliferation and apoptosis.
  • To examine the expression levels of COX enzymes in HNSCC cells under NSAID treatment.

Main Methods:

  • Utilized HNSCC cell lines SCC-9 and SCC-25.
  • Assayed cell numbers and apoptosis using cell counting, immunofluorescence, and fluorescence-activated cell sorting (FACS).
  • Analyzed cyclooxygenase (COX) expression via Western blotting.

Main Results:

  • Both investigated HNSCC cell lines express COX-1 and COX-2.
  • Nimesulide and indomethacin treatment led to increased apoptosis and reduced cell numbers.
  • NSAID incubation resulted in the upregulation of COX-2 expression.

Conclusions:

  • NSAIDs, particularly COX inhibitors, demonstrate anti-cancer activity in HNSCC cell lines.
  • These findings suggest a potential therapeutic role for COX inhibitors in the treatment and prevention of HNSCC.
  • Further research into NSAIDs for HNSCC management is warranted based on observed anti-cancer effects.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...